Galderma Group AG (GALDY)
OTCMKTS · Delayed Price · Currency is USD
40.44
+0.27 (0.67%)
At close: Feb 18, 2026
Galderma Group AG Revenue
Galderma Group AG had revenue of $2.47B in the half year ending June 30, 2025, with 22.38% growth. This brings the company's revenue in the last twelve months to $4.69B, up 8.62% year-over-year. In the year 2024, Galderma Group AG had annual revenue of $4.44B with 7.85% growth.
Revenue (ttm)
4.69B
Revenue Growth
+8.62%
P/S Ratio
10.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
48.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.44B | 323.00M | 7.85% |
| Dec 31, 2023 | 4.12B | 293.10M | 7.66% |
| Dec 31, 2022 | 3.82B | 378.90M | 11.00% |
| Dec 31, 2021 | 3.45B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGalderma Group AG News
- 2 days ago - Galderma Announces Appointment of New Chief Financial Officer - Business Wire
- 6 days ago - We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra's Regenerative Properties - Business Wire
- 7 days ago - Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™ - Business Wire
- 16 days ago - Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission - Business Wire
- 19 days ago - Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity - Business Wire
- 20 days ago - Galderma Unveils ‘Wake Up To Restylane', Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty - Business Wire
- 27 days ago - IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry's Broadest Injectable Aesthetics Portfolio - Business Wire
- 4 weeks ago - Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership - Business Wire